Healthcare -
Biotechnology - NASDAQ - CA
$ 1.75
0 %
$ 77.6 M
Market Cap
-2.73
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart EPIX
FINANCIALS
Balance Sheet
ESSA Pharma Inc.
| Current Assets | 128 M |
| Cash & Short-Term Investments | 127 M |
| Receivables | 163 K |
| Other Current Assets | 636 K |
| Non-Current Assets | 552 K |
| Long-Term Investments | 0 |
| PP&E | 295 K |
| Other Non-Current Assets | 257 K |
| Current Liabilities | 3.3 M |
| Accounts Payable | 2.4 M |
| Short-Term Debt | 124 K |
| Other Current Liabilities | 773 K |
| Non-Current Liabilities | 205 K |
| Long-Term Debt | 205 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
ESSA Pharma Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 21.2 M |
| Operating Income | 0 |
| Other Expenses | 28.5 M |
| Net Income | -28.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ESSA Pharma Inc.
| Net Income | -28.5 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 6.54 M |
| Change in Working Capital | -419 K |
| Others | -712 K |
| Free Cash Flow | -22.7 M |
Wall Street Analysts Price Targets
ESSA Pharma Inc.
Wall Street analysts predict an average 1-year price target for EPIX of $11.3 , with forecasts ranging from
a
low of
$2 to a high of $17 .
EPIX Lowest Price Target
Wall Street Target
2 USD
14.29%
EPIX Average Price Target
Wall Street Target
11.3 USD
547.62%
EPIX Highest Price Target
Wall Street Target
17 USD
871.43%
4. DIVIDEND
ANALYSIS
EPIX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ESSA Pharma Inc.
Sold
0-3 MONTHS
12 M USD 1
3-6 MONTHS
16.7 K USD 1
6-9 MONTHS
4.82 K USD 1
9-12 MONTHS
789 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Nov 01, 2024
|
Sell 3.06 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 2000000
|
1.532 USD |
|
2 months ago
Nov 01, 2024
|
Sell 3.05 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 2000000
|
1.5259 USD |
|
2 months ago
Nov 01, 2024
|
Sell 3.06 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 2000000
|
1.5294 USD |
|
2 months ago
Nov 01, 2024
|
Sell 2.84 M
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 1879583
|
1.513 USD |
|
4 months ago
Sep 09, 2024
|
Sell 4.16 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
6 USD |
|
4 months ago
Sep 03, 2024
|
Sell 12.6 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 2082
|
6.03 USD |
|
8 months ago
May 06, 2024
|
Sell 4.82 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
6.95 USD |
|
9 months ago
Apr 05, 2024
|
Sell 5.51 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
7.94 USD |
|
10 months ago
Mar 05, 2024
|
Sell 6.23 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
8.98 USD |
|
11 months ago
Feb 06, 2024
|
Sell 749 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 72782
|
10.29 USD |
|
11 months ago
Feb 05, 2024
|
Sell 6.42 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 694
|
9.25 USD |
|
11 months ago
Feb 05, 2024
|
Sell 5.02 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 500
|
10.04 USD |
|
1 year ago
Jan 16, 2024
|
Sell 17.2 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 1718
|
10.01 USD |
|
1 year ago
Jan 05, 2024
|
Sell 4.27 K
USD
|
Virsik Peter
Chief Operating Officer
|
- 699
|
6.11 USD |
|
1 year ago
Dec 14, 2023
|
Bought
21.2 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 9223
|
2.3 USD |
|
1 year ago
Nov 21, 2023
|
Bought
133 K USD
|
BERGER FRANKLIN M
Director
|
+ 23259
|
5.73 USD |
|
1 year ago
Nov 03, 2023
|
Bought
98.7 K USD
|
BERGER FRANKLIN M
Director
|
+ 16471
|
5.99 USD |
|
1 year ago
Nov 02, 2023
|
Bought
321 K USD
|
BERGER FRANKLIN M
Director
|
+ 60000
|
5.35 USD |
|
2 years ago
Dec 30, 2022
|
Bought
7.97 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 3067
|
2.6 USD |
|
2 years ago
Dec 22, 2022
|
Bought
51.1 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 21367
|
2.39 USD |
|
2 years ago
Dec 14, 2022
|
Sell 75 K
USD
|
BERGER FRANKLIN M
Director
|
- 25000
|
3 USD |
|
2 years ago
Dec 15, 2022
|
Sell 92.8 K
USD
|
BERGER FRANKLIN M
Director
|
- 32000
|
2.9 USD |
|
2 years ago
Dec 15, 2022
|
Sell 143 K
USD
|
BERGER FRANKLIN M
Director
|
- 50000
|
2.86 USD |
|
2 years ago
Dec 16, 2022
|
Sell 134 K
USD
|
BERGER FRANKLIN M
Director
|
- 50000
|
2.67 USD |
|
2 years ago
Dec 20, 2022
|
Sell 110 K
USD
|
BERGER FRANKLIN M
Director
|
- 43617
|
2.53 USD |
|
2 years ago
Dec 21, 2022
|
Sell 91.3 K
USD
|
BERGER FRANKLIN M
Director
|
- 37889
|
2.41 USD |
|
2 years ago
Dec 21, 2022
|
Sell 83.1 K
USD
|
BERGER FRANKLIN M
Director
|
- 34334
|
2.42 USD |
|
2 years ago
Dec 30, 2022
|
Bought
21.6 K USD
|
Wood David S.
Chief Financial Officer
|
+ 8302
|
2.6 USD |
|
2 years ago
Oct 27, 2022
|
Bought
2.25 M USD
|
BIOTECH GROWTH N V
Director
|
+ 500000
|
4.5022 USD |
|
2 years ago
Oct 26, 2022
|
Bought
5.97 M USD
|
BIOTECH GROWTH N V
Director
|
+ 1500000
|
3.979 USD |
|
2 years ago
Jul 18, 2022
|
Bought
947 K USD
|
BB BIOTECH AG
director:
|
+ 300000
|
3.1558 USD |
|
2 years ago
Jul 18, 2022
|
Bought
947 K USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 300000
|
3.1558 USD |
|
2 years ago
Jul 15, 2022
|
Bought
757 K USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 241665
|
3.1316 USD |
|
2 years ago
Jul 14, 2022
|
Bought
969 K USD
|
BB BIOTECH AG
director:
|
+ 347204
|
2.7921 USD |
|
2 years ago
Jul 14, 2022
|
Bought
969 K USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 347204
|
2.7921 USD |
|
2 years ago
Jun 30, 2022
|
Bought
14.5 K USD
|
Parkinson David Ross
Chief Executive Officer
|
+ 4887
|
2.958 USD |
|
2 years ago
Apr 27, 2022
|
Sell 147 K
USD
|
BB BIOTECH AG
director:
|
- 25100
|
5.8536 USD |
|
2 years ago
Apr 27, 2022
|
Sell 147 K
USD
|
BIOTECH GROWTH N V
10 percent owner
|
- 25100
|
5.8536 USD |
|
3 years ago
Aug 18, 2021
|
Bought
2.22 M USD
|
BIOTECH GROWTH N V
10 percent owner
|
+ 250000
|
8.8752 USD |
|
3 years ago
Feb 22, 2021
|
Bought
1.54 M USD
|
BERGER FRANKLIN M
Director
|
+ 57000
|
27 USD |
|
21 years ago
Dec 03, 2003
|
Sell 94.3 K
USD
|
CROOKE STANLEY T
Director
|
- 5000
|
18.865 USD |
|
21 years ago
Dec 02, 2003
|
Sell 175 K
USD
|
CROOKE STANLEY T
Director
|
- 9500
|
18.4279 USD |
|
21 years ago
Dec 01, 2003
|
Sell 81.4 K
USD
|
CROOKE STANLEY T
Director
|
- 4500
|
18.0856 USD |
|
21 years ago
Nov 26, 2003
|
Sell 93.9 K
USD
|
CROOKE STANLEY T
Director
|
- 5300
|
17.7189 USD |
|
21 years ago
Nov 25, 2003
|
Sell 148 K
USD
|
CROOKE STANLEY T
Director
|
- 8401
|
17.6536 USD |
|
21 years ago
Nov 24, 2003
|
Sell 14.4 K
USD
|
CROOKE STANLEY T
Director
|
- 823
|
17.5414 USD |
|
21 years ago
Nov 21, 2003
|
Sell 180 K
USD
|
CROOKE STANLEY T
Director
|
- 10104
|
17.8367 USD |
7. News
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of masofaniten, and withdraw the related IND and CTAs, based on an interim analysis of the data from the Phase 2 combination study, concluding that masofaniten combined with enzalutamide was unlikely to meet its primary endpoint," said David Parkinson, MD, President and CEO of ESSA.
prnewswire.com
- 1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
- 1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accesswire.com
- 1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accesswire.com
- 1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
- 1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accesswire.com
- 1 month ago
Lost Money on ESSA Pharma Inc.(EPIX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
accesswire.com
- 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
prnewswire.com
- 2 months ago
EPIX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your ESSA Pharma Inc. investment
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
accesswire.com
- 2 months ago
ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
accesswire.com
- 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
accesswire.com
- 2 months ago
ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
accesswire.com
- 2 months ago
8. Profile
Summary
ESSA Pharma Inc. EPIX
COUNTRY
CA
INDUSTRY
Biotechnology
MARKET CAP
$ 77.6 M
Dividend Yield
0.00%
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Contact
999 West Broadway, Vancouver, BC, V5Z 1K5
https://www.essapharma.com
IPO
Date
March 13, 2015
Employees
50
Officers
Dr. David Ross Parkinson M.D.
President, Chief Executive Officer & Director
Dr. Alessandra Cesano M.D., Ph.D.
Chief Medical Officer & Executive Vice President
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA
Chief Financial Officer
Mr. Peter A. Virsik M.B.A., M.S.
Executive Vice President & Chief Operating Officer
Chandtip Chandhasin
Executive
Erica Osbourne
Executive
Erin Rudsinski
Executive
Loleta Harris
Executive
Neil Thapar
Executive
Nkengyal Barber
Executive